HDI (Hypertension Diagnostics) issued key US patent:
This article was originally published in Clinica
Hypertension Diagnostics (HDI) has gained what it claims is a significant US patent relating to the core technology in its cardiovascular profiling systems. The patent describes methods and apparatus for processing an arterial blood pressure waveform in order to extract clinically useful information regarding the state of the cardiovascular system. HDI's products can provide blood pressure values and non-invasively detect changes in the compliance or elasticity of large and small arteries. Changes in elasticity can indicate whether a patient has underlying vascular disease that might require further evaluation, says the St Paul, Minnesota firm.
You may also be interested in...
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.
February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.